TY - JOUR
T1 - Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage
AU - Netzel, Brian C.
AU - Charlesworth, M. Cristine
AU - Johnson, Kenneth L.
AU - French, Amy J.
AU - Dispenzieri, Angela
AU - Maleszewski, Joseph J.
AU - McPhail, Ellen D.
AU - Grogan, Martha
AU - Redfield, Margaret M.
AU - Weivoda, Megan
AU - Muchtar, Eli
AU - Gertz, Morie A.
AU - Kumar, Shaji K.
AU - Misra, Pinaki
AU - Vrana, Julie
AU - Theis, Jason
AU - Hayman, Suzanne R.
AU - Ramirez-Alvarado, Marina
AU - Dasari, Surendra
AU - Kourelis, Taxiarchis
N1 - Publisher Copyright:
© 2025 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Background: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque proteome, which may not capture tissue-wide proteomic alterations. Objectives: To evaluate mechanisms of tissue dysfunction in cardiac AL and ATTR using a full biopsy tissue proteomics approach. Methods: We performed proteomics analysis on 76 ATTR and 27 AL diagnostic endomyocardial biopsies. Results: Stage-3 AL patients exhibited increased coagulation, extracellular matrix remodelling (ECM), epithelial-to-mesenchymal transition (EMT), complement activation, hypoxia, and clathrin-mediated endocytosis pathways vs. stages-1/2, with decreased healthy cardiac metabolism. In stages-2 and 3 ATTR, immunoglobulin proteins, complement, and keratinisation pathways were increased compared to stage-1. Unsupervised analyses identified an ATTR group with worse survival characterised by upregulated complement and downregulated metabolic pathways. Compared to ATTR, AL had higher clathrin-mediated endocytosis, mRNA splicing, and ribosomal proteins, while ATTR had higher complement levels. Conclusions: This study identifies known processes dysregulated in heart failure with preserved ejection fraction as well as novel pathways responsible for tissue damage. Our results support an immune-mediated mechanism of tissue toxicity in cardiac amyloidosis, especially among patients with worse outcomes.
AB - Background: Cardiac AL and ATTR are potentially fatal cardiomyopathies. Current therapies do not address mechanisms of tissue dysfunction because these remain unknown. Our prior work focused on the amyloid plaque proteome, which may not capture tissue-wide proteomic alterations. Objectives: To evaluate mechanisms of tissue dysfunction in cardiac AL and ATTR using a full biopsy tissue proteomics approach. Methods: We performed proteomics analysis on 76 ATTR and 27 AL diagnostic endomyocardial biopsies. Results: Stage-3 AL patients exhibited increased coagulation, extracellular matrix remodelling (ECM), epithelial-to-mesenchymal transition (EMT), complement activation, hypoxia, and clathrin-mediated endocytosis pathways vs. stages-1/2, with decreased healthy cardiac metabolism. In stages-2 and 3 ATTR, immunoglobulin proteins, complement, and keratinisation pathways were increased compared to stage-1. Unsupervised analyses identified an ATTR group with worse survival characterised by upregulated complement and downregulated metabolic pathways. Compared to ATTR, AL had higher clathrin-mediated endocytosis, mRNA splicing, and ribosomal proteins, while ATTR had higher complement levels. Conclusions: This study identifies known processes dysregulated in heart failure with preserved ejection fraction as well as novel pathways responsible for tissue damage. Our results support an immune-mediated mechanism of tissue toxicity in cardiac amyloidosis, especially among patients with worse outcomes.
KW - Amyloidosis
KW - complement
KW - light chain
KW - proteomics
KW - tissue damage
KW - transthyretin
UR - http://www.scopus.com/inward/record.url?scp=85214405503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85214405503&partnerID=8YFLogxK
U2 - 10.1080/13506129.2024.2448440
DO - 10.1080/13506129.2024.2448440
M3 - Article
AN - SCOPUS:85214405503
SN - 1350-6129
VL - 32
SP - 72
EP - 80
JO - Amyloid
JF - Amyloid
IS - 1
ER -